Sign in to view content

Two-Year Results From the Subretinal RGX-314 Gene Therapy Phase 1/2a Study for the Treatment of Neovascular AMD

Robert L. Avery, MD

Video
Published 2021

Related

Percentage of Patients Maintained on Quarterly Anti-VEGF Dosing for the Treatment of Neovascular Age-Related Macular Degeneration Across Key Clinical Trials
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2018
Anti-VEGF Injections and Risk of Traction Retinal Detachments in Eyes With Proliferative Diabetic Retinopathy: Pooled Analysis of 5 DRCR.net Trials
Hani Salehi-Had, MD, FASRS
Updates from the Field
Types of Strokes Seen in Patients
Sophie Jane Bakri, MD
Updates from the Field
2017

Category: AMD-Neovascular

See more